Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for DFTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 758.70M
March 31, 2026 5.309M
December 31, 2025 246.10M
September 30, 2025 0.7136M
June 30, 2025 20.01M
March 31, 2025 1.002M
December 31, 2024 -0.7001M
September 30, 2024 69.66M
June 30, 2024 9.514M
March 31, 2024 169.25M
December 31, 2023 2.314M
September 30, 2023 17.47M
June 30, 2023 1.281M
March 31, 2023 0.583M
December 31, 2022 -0.9709M
September 30, 2022 57.17M
June 30, 2022 0.5883M
March 31, 2022 -0.166M
December 31, 2021
Date Value
September 30, 2021 -1.140M
June 30, 2021 9.409M
March 31, 2021 89.99M
December 31, 2020 71.87M
September 30, 2020 0.7571M
June 30, 2020 8.703M
March 31, 2020 18.91M
August 31, 2019 -0.0054M
May 31, 2019 -0.0019M
February 28, 2019 0.2965M
November 30, 2018 0.00
August 31, 2018 0.3198M
May 31, 2018 -0.0125M
February 28, 2018 0.0128M
November 30, 2017 -0.0157M
August 31, 2017 0.2145M
May 31, 2017 1.808M
February 28, 2017 1.709M
November 30, 2016 0.7329M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
CNBX Pharmaceuticals, Inc. 0.045M
GB Sciences, Inc. --
Arvinas, Inc. 0.40M
Fulcrum Therapeutics, Inc. 0.356M